Bloom X³ Co., Ltd. (Headquarters: Tokyo; Founder & CEO: Hiromichi Kimura, Ph.D., R.Ph.) is pleased to announce that its research collaboration with Kansai BNCT Medical Center, Osaka Medical and Pharmaceutical University (Director: Prof. Koji Ono), has formally advanced to its second phase under a newly executed research collaboration agreement. The work is being carried out within an integrated environment that includes access to the accelerator-based BNCT system (NeuCure®) installed at the Center.
The Company’s 1102 Program is a proprietary drug discovery program devoted to creating next-generation boron compounds that draw out the full therapeutic potential of Boron Neutron Capture Therapy (BNCT). Through the dedicated cooperation of all those involved, the program has steadily built a body of preliminary findings. With this agreement now in place, the work moves beyond the stage of confirming early scientific signals, into a deeper phase of hypothesis validation and translational implementation—a new horizon for the research.
Kansai BNCT Medical Center stands as a central hub for BNCT in Japan, advancing research, clinical practice, and human-resource development as three integrated pillars. Grounded in the refined technical traditions Japan has cultivated in this field over decades—including the world’s first clinical deployment of an accelerator-based BNCT system and the body of insured clinical experience built upon it—the Center offers an environment singular in the world, where research and clinical practice advance hand in hand. It is precisely the kind of fertile ground required to bring genuinely transformative therapies into the world. Its Director, Prof. Koji Ono, has led BNCT research for over half a century, dating back to the reactor era, and is widely recognized as one of the foremost authorities in the field. Guided by his enduring expertise and clinical insight, Bloom X³ is committed to building, with integrity and care, a body of work of true scientific consequence—step by deliberate step.
In advancing this program, Bloom X³ draws upon a deliberately constructed network of strategic research partnerships with leading academic institutions across Japan, each engaged with intent—matched to the specific phase and scientific domain of the work. Alongside the central hub for the clinical translation of BNCT, the Company has cultivated close research relationships with institutions at the forefront of geroscience and regenerative medicine, weaving these threads together into a coherent whole. To an outside observer this architecture may appear unconventional; in truth, it is a quietly rational design—engineered to support the full arc of the 1102 Program, from intractable cancers through aging, rejuvenation, and the regenerative frontier, a trajectory no single institution alone could carry.
While the 1102 Program is, in the near term, focused on establishing a novel treatment modality for intractable cancers, its longer trajectory reaches further still: toward applications in aging, rejuvenation, and regenerative medicine—the emerging frontier of next-generation therapeutics. Beginning from oncology, a domain humanity has long contended with, the program looks toward a form of medicine that engages with the very arc of biological time. That widening horizon, we observe quietly—but with conviction.
Comment from Hiromichi Kimura, Ph.D., R.Ph., Founder & CEO
“Kansai BNCT Medical Center is a rare setting in global medicine—grounded in Japan’s refined technical heritage, and uniquely structured to advance research and clinical practice as a single, integrated whole. Advancing into Phase 2 alongside this world-leading accelerator-based BNCT clinical infrastructure represents a significant step forward for our Company. Our 1102 Program is initially focused on establishing a novel treatment modality for intractable cancers, while looking ahead to broader applications in aging, rejuvenation, and regenerative medicine—the frontier of next-generation therapeutics. This wider trajectory is sustained by a network of strategic research partnerships, purposefully matched to leading academic institutions across Japan in each relevant domain. We extend our sincere gratitude to Director Koji Ono and to all those whose efforts make this collaboration possible.”
About Bloom X³
Bloom X³ Co., Ltd. is a life sciences venture studio operating an integrated platform comprising NewXus Fund, Yncubator, and Zero1 IP Access. The 1102 Program, advanced under Yncubator, stands as the cornerstone of the Company’s proprietary drug discovery pipeline.
Corporate information: https://bloomx3.com
日本語版はこちら: 大阪医科薬科大学 BNCT共同臨床研究所との共同研究、第2フェーズへ移行
